ASX - By Stock
|
BCT |
Re:
Ann: Bluechiip raises $1.63 million
|
|
second opinion
|
21 |
4.2K |
0 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
21
|
4.2K
|
0
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Bluechiip raises $1.63 million
|
|
second opinion
|
21 |
4.2K |
2 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
21
|
4.2K
|
2
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Trading Halt
|
|
second opinion
|
56 |
9.9K |
0 |
17/10/23 |
17/10/23 |
ASX - By Stock
|
56
|
9.9K
|
0
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Trading Halt
|
|
second opinion
|
56 |
9.9K |
0 |
16/10/23 |
16/10/23 |
ASX - By Stock
|
56
|
9.9K
|
0
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Bluechiip Market Update
|
|
second opinion
|
16 |
3.6K |
0 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
16
|
3.6K
|
0
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Avecho raises further $6M for Phase III trial
|
|
second opinion
|
130 |
27K |
2 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
130
|
27K
|
2
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
second opinion
|
1 |
416 |
1 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
1
|
416
|
1
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Bluechiip Market Update
|
|
second opinion
|
58 |
14K |
5 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
58
|
14K
|
5
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Bluechiip Market Update
|
|
second opinion
|
58 |
14K |
4 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
58
|
14K
|
4
|
|
ASX - By Stock
|
BCT |
Re:
Ann: FY23 Annual Report
|
|
second opinion
|
36 |
8.3K |
4 |
05/09/23 |
05/09/23 |
ASX - By Stock
|
36
|
8.3K
|
4
|
|
ASX - By Stock
|
BCT |
Re:
Ann: FY23 Annual Report
|
|
second opinion
|
36 |
8.3K |
1 |
05/09/23 |
05/09/23 |
ASX - By Stock
|
36
|
8.3K
|
1
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Clinical CBD program expands with the Lambert Initiative
|
|
second opinion
|
31 |
8.6K |
2 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
31
|
8.6K
|
2
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Avecho receives ethics approval for Phase III CBD trial
|
|
second opinion
|
71 |
21K |
2 |
28/12/22 |
28/12/22 |
ASX - By Stock
|
71
|
21K
|
2
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Avecho receives ethics approval for Phase III CBD trial
|
|
second opinion
|
71 |
21K |
12 |
23/12/22 |
23/12/22 |
ASX - By Stock
|
71
|
21K
|
12
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Suspension from Official Quotation - AVEO
|
|
second opinion
|
14 |
5.4K |
2 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
14
|
5.4K
|
2
|
|
ASX - By Stock
|
NMT |
Re:
General Neometals related news
|
|
second opinion
|
4.4K |
2.0M |
0 |
01/06/22 |
01/06/22 |
ASX - By Stock
|
4.4K
|
2.0M
|
0
|
|
ASX - By Stock
|
EVS |
Re:
Ann: EVS Water Update
|
|
second opinion
|
17 |
6.6K |
0 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
17
|
6.6K
|
0
|
|
ASX - By Stock
|
EVS |
Re:
Ann: EVS Water Update
|
|
second opinion
|
17 |
6.6K |
3 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
17
|
6.6K
|
3
|
|
ASX - By Stock
|
AVE |
Re:
Ann: March 2022 Quarterly Activities Report & Appendix 4C
|
|
second opinion
|
4 |
1.9K |
6 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
4
|
1.9K
|
6
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
second opinion
|
8 |
3.4K |
5 |
28/04/22 |
28/04/22 |
ASX - By Stock
|
8
|
3.4K
|
5
|
|
ASX - By Stock
|
AVE |
Re:
Ann: AVE license agreement for US recreational cannabis market
|
|
second opinion
|
125 |
29K |
1 |
02/02/22 |
02/02/22 |
ASX - By Stock
|
125
|
29K
|
1
|
|
ASX - By Stock
|
AVE |
Re:
Ann: AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis
|
|
second opinion
|
80 |
18K |
3 |
04/01/22 |
04/01/22 |
ASX - By Stock
|
80
|
18K
|
3
|
|
ASX - By Stock
|
BCT |
Re:
Chart - BCT
|
|
second opinion
|
116 |
31K |
9 |
31/12/21 |
31/12/21 |
ASX - By Stock
|
116
|
31K
|
9
|
|
ASX - By Stock
|
AVE |
Re:
Ann: AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis
|
|
second opinion
|
80 |
18K |
3 |
21/12/21 |
21/12/21 |
ASX - By Stock
|
80
|
18K
|
3
|
|
ASX - By Stock
|
AVE |
Re:
Ann: AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis
|
|
second opinion
|
80 |
18K |
0 |
21/12/21 |
21/12/21 |
ASX - By Stock
|
80
|
18K
|
0
|
|
ASX - By Stock
|
AVE |
Re:
Ann: AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis
|
|
second opinion
|
80 |
18K |
1 |
21/12/21 |
21/12/21 |
ASX - By Stock
|
80
|
18K
|
1
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Positive results from Avecho's Phase I trial of CBD soft-gel
|
|
second opinion
|
50 |
12K |
1 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
50
|
12K
|
1
|
|
ASX - By Stock
|
AVE |
Re:
Clinical Trial Thread
|
|
second opinion
|
59 |
11K |
4 |
07/12/21 |
07/12/21 |
ASX - By Stock
|
59
|
11K
|
4
|
|
ASX - By Stock
|
AVE |
Re:
Clinical Trial Thread
|
|
second opinion
|
59 |
11K |
4 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
59
|
11K
|
4
|
|
ASX - By Stock
|
AVE |
Re:
Clinical Trial Thread
|
|
second opinion
|
59 |
11K |
2 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
59
|
11K
|
2
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Bluechiip secures FDA Registration and CE IVD Certification
|
|
second opinion
|
18 |
4.9K |
4 |
30/11/21 |
30/11/21 |
ASX - By Stock
|
18
|
4.9K
|
4
|
|
ASX - By Stock
|
AVE |
Re:
Clinical Trial Thread
|
|
second opinion
|
59 |
11K |
2 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
59
|
11K
|
2
|
|
ASX - By Stock
|
BCT |
Re:
ASX Semiconductor Conference 30 November
|
|
second opinion
|
6 |
2.2K |
4 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
6
|
2.2K
|
4
|
|
ASX - By Stock
|
BCT |
Re:
Ann: AGM Presentation
|
|
second opinion
|
10 |
2.5K |
3 |
28/11/21 |
28/11/21 |
ASX - By Stock
|
10
|
2.5K
|
3
|
|
ASX - By Stock
|
AVE |
Re:
Clinical Trial Thread
|
|
second opinion
|
59 |
11K |
1 |
14/11/21 |
14/11/21 |
ASX - By Stock
|
59
|
11K
|
1
|
|
ASX - By Stock
|
AVE |
Re:
Clinical Trial Thread
|
|
second opinion
|
59 |
11K |
3 |
14/11/21 |
14/11/21 |
ASX - By Stock
|
59
|
11K
|
3
|
|
ASX - By Stock
|
AVE |
Re:
Clinical Trial Thread
|
|
second opinion
|
59 |
11K |
3 |
14/11/21 |
14/11/21 |
ASX - By Stock
|
59
|
11K
|
3
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Open Briefing
|
|
second opinion
|
76 |
17K |
2 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
76
|
17K
|
2
|
|
ASX - By Stock
|
BCT |
Re:
Ann: Open Briefing
|
|
second opinion
|
76 |
17K |
5 |
28/10/21 |
28/10/21 |
ASX - By Stock
|
76
|
17K
|
5
|
|
ASX - By Stock
|
BCT |
Re:
Ann: License Agreement with Fujifilm Irvine Scientific
|
|
second opinion
|
54 |
14K |
3 |
26/10/21 |
26/10/21 |
ASX - By Stock
|
54
|
14K
|
3
|
|
ASX - By Stock
|
BCT |
Re:
Ann: License Agreement with Fujifilm Irvine Scientific
|
|
second opinion
|
54 |
14K |
6 |
26/10/21 |
26/10/21 |
ASX - By Stock
|
54
|
14K
|
6
|
|
ASX - By Stock
|
BCT |
Re:
Ann: License Agreement with Fujifilm Irvine Scientific
|
|
second opinion
|
54 |
14K |
10 |
26/10/21 |
26/10/21 |
ASX - By Stock
|
54
|
14K
|
10
|
|
ASX - By Stock
|
BCT |
Re:
Ann: License Agreement with Fujifilm Irvine Scientific
|
|
second opinion
|
54 |
14K |
8 |
26/10/21 |
26/10/21 |
ASX - By Stock
|
54
|
14K
|
8
|
|
ASX - By Stock
|
BCT |
Re:
Bluechiip Progress
|
|
second opinion
|
14 |
3.3K |
3 |
24/10/21 |
24/10/21 |
ASX - By Stock
|
14
|
3.3K
|
3
|
|
ASX - By Stock
|
BCT |
Re:
Bluechiip Progress
|
|
second opinion
|
14 |
3.3K |
1 |
24/10/21 |
24/10/21 |
ASX - By Stock
|
14
|
3.3K
|
1
|
|
ASX - By Stock
|
BCT |
Re:
Bluechiip Progress
|
|
second opinion
|
14 |
3.3K |
1 |
20/10/21 |
20/10/21 |
ASX - By Stock
|
14
|
3.3K
|
1
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Dosing begins in Phase I PK trial testing CBD soft-gel
|
|
second opinion
|
37 |
9.3K |
2 |
18/10/21 |
18/10/21 |
ASX - By Stock
|
37
|
9.3K
|
2
|
|
ASX - By Stock
|
BCT |
Re:
BoxTracker
|
|
second opinion
|
17 |
5.7K |
3 |
20/09/21 |
20/09/21 |
ASX - By Stock
|
17
|
5.7K
|
3
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Phase I clinical trial testing CBD product-enrolment begins
|
|
second opinion
|
34 |
7.5K |
0 |
17/09/21 |
17/09/21 |
ASX - By Stock
|
34
|
7.5K
|
0
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Phase I clinical trial testing CBD product-enrolment begins
|
|
second opinion
|
34 |
7.5K |
0 |
17/09/21 |
17/09/21 |
ASX - By Stock
|
34
|
7.5K
|
0
|
|